

Suzanne E Schindler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3199744/publications.pdf>

Version: 2024-02-01

57
papers

2,425
citations

279798

23
h-index

223800

46
g-index

57
all docs

57
docs citations

57
times ranked

3216
citing authors

#	ARTICLE	IF	CITATIONS
1	High-precision plasma A β -amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , 2019, 93, e1647-e1659.	1.1	514
2	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 264.	9.0	227
3	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's and Dementia</i> , 2018, 14, 1460-1469.	0.8	192
4	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1505-1521.	0.8	163
5	Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. <i>Neurology</i> , 2022, 98, .	1.1	89
6	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	78
7	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. <i>Neurology</i> , 2019, 92, e1567-e1579.	1.1	73
8	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 655-665.	0.8	72
9	Photo-activatable Cre recombinase regulates gene expression in vivo. <i>Scientific Reports</i> , 2015, 5, 13627.	3.3	70
10	Effect of Race on Prediction of Brain Amyloidosis by Plasma A β 42/A β 40, Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.1	63
11	Addressing Health Disparities Among Minority Populations. <i>JAMA Neurology</i> , 2020, 77, 1063.	9.0	60
12	Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome. <i>Neurologist</i> , 2016, 21, 112-117.	0.7	58
13	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2017, 56, 25-32.	3.1	57
14	Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , 2018, 14, 62-70.	0.8	50
15	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 745-756.	2.6	45
16	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 1149-1159.	0.8	45
17	Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review. <i>JAMIA Open</i> , 2021, 4, ooab052.	2.0	44
18	Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. <i>Annals of Neurology</i> , 2021, 89, 254-265.	5.3	42

#	ARTICLE	IF	CITATIONS
19	GPS driving: a digital biomarker for preclinical Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 115.	6.2	42
20	Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. <i>Neurology</i> , 2018, 91, e436-e443.	1.1	38
21	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. <i>Neurology</i> , 2021, 97, e1823-e1834.	1.1	35
22	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. <i>Neurology: Genetics</i> , 2021, 7, e571.	1.9	27
23	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. <i>NeuroImage</i> , 2022, 256, 119228.	4.2	27
24	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. <i>Brain</i> , 2018, 141, 3233-3248.	7.6	24
25	Comparative analytical performance of multiple plasma A β ²⁴² and A β ²⁴⁰ assays and their ability to predict positron emission tomography amyloid positivity. <i>Alzheimer's and Dementia</i> , 2023, 19, 956-966.	0.8	24
26	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , 2019, 2, e1917126.	5.9	23
27	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. <i>Neurobiology of Disease</i> , 2022, 166, 105662.	4.4	21
28	Combining blood-based biomarkers to predict risk for Alzheimer's disease dementia. <i>Nature Aging</i> , 2021, 1, 26-28.	11.6	20
29	Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1085-1095.	2.6	18
30	Obesity and White Matter Neuroinflammation Related Edema in Alzheimer's Disease Dementia Biomarker Negative Cognitively Normal Individuals. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1801-1811.	2.6	18
31	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	1.7	18
32	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. <i>Neurology</i> , 2021, 97, e76-e87.	1.1	17
33	A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease. <i>Brain Communications</i> , 2022, 4, fcac045.	3.3	17
34	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	16
35	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1119-1129.	2.6	14
36	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. <i>JAMA Network Open</i> , 2019, 2, e1913491.	5.9	11

#	ARTICLE	IF	CITATIONS
37	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 27-31.	2.6	8
38	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. <i>BMJ Open</i> , 2021, 11, e050820.	1.9	8
39	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 2570-2581.	0.8	8
40	Network dysfunction in cognitively normal APOE ϵ 4 carriers is related to subclinical tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 116-126.	0.8	7
41	Cognitively normal APOE ϵ 4 carriers have specific elevation of CSF SNAP-25. <i>Neurobiology of Aging</i> , 2021, 102, 64-72.	3.1	7
42	Sex-Specific Patterns of Body Mass Index Relationship with White Matter Connectivity. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1831-1848.	2.6	7
43	Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease. <i>Sleep</i> , 2022, 45, .	1.1	7
44	Fluid Biomarkers in Dementia Diagnosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 822-833.	0.8	6
45	Double Monoclonal Immunoassay for Quantifying Human Visinin-Like Protein-1 in CSF. <i>Clinical Chemistry</i> , 2017, 63, 603-604.	3.2	4
46	CSF sTREM2: marking the tipping point between preclinical AD and dementia?. <i>EMBO Molecular Medicine</i> , 2016, 8, 437-438.	6.9	3
47	Advances in diagnostic testing for Alzheimer disease. <i>Missouri Medicine</i> , 2013, 110, 401-5.	0.3	3
48	COVID-19 and preclinical Alzheimer disease: Driving, mobility, activity and experiences of older adults in the United States. <i>Alzheimer's and Dementia</i> , 2021, 17, e057692.	0.8	2
49	O1-05-03: Upward Drift in CSF AB42 Values over 10 Years. , 2016, 12, P183-P183.		1
50	P1-006: Emerging CSF Biomarkers of Neuroinflammation, Neuronal Injury And Synaptic Integrity in the Adni Cohort. , 2016, 12, P399-P399.		1
51	Predicting Symptom Onset in Sporadic Alzheimer's Disease: "How Long Do I Have?" <i>Journal of Alzheimer's Disease</i> , 2022, , 1-5.	2.6	1
52	[P3-205]: EMERGING CSF BIOMARKERS AS PREDICTORS OF ALZHEIMER DISEASE DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1014.	0.8	0
53	[O2-05-03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND IN VIVO AMYLOID IMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P561.	0.8	0
54	O3-14-01: NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIP1, NEUROGRANIN, SNAP25 AND YKL40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). <i>Alzheimer's and Dementia</i> , 2018, 14, P1059.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Racial differences in Alzheimer biomarkers among early-stage symptomatic and cognitively normal Alzheimer Disease Research Center (ADRC) participants. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
56	Presence of co-pathology in sporadic early-onset Alzheimer disease versus dominantly inherited Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2021, 17, e055045.	0.8	0
57	<scp>ANA</scp> Investigates: The Future of Biomarkers in Alzheimer Disease. <i>Annals of Neurology</i> , 2022, 92, 159-160.	5.3	0